3 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
We hypothesize that formerly pre-eclamptic women have persistently increased angiotensin II sensitivity, sodium sensitivity, insulin resistance and sympathetic nerve activity together initially leading to susceptibility for early renal disease and…
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.